

Date: April 22, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051
Scrip Symbol: SUVENPHAR

Sub: Intimation of approval by Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Ref: Scheme of Amalgamation of Cohance Lifesciences Limited with and into Suven Pharmaceuticals Limited under Sections 230 to 232 of the Companies Act, 2013 (“Act”), the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder (“Scheme of Amalgamation”)

Dear Sir/Madam,

This is with reference to, and in furtherance of:

- (a) our letter dated February 29, 2024, regarding the decision of the Board of Directors of Suven Pharmaceuticals Limited (“Transferee Company”) approving the Scheme of Amalgamation of Cohance Lifesciences Limited (“Transferor Company”) with and into Transferee Company under Sections 230 to 232 of the Act and other applicable rules and / or regulations, subject to receipt of applicable regulatory and other approvals;
- (b) our letter dated October 22, 2024, regarding the order dated October 22, 2024 passed by Hon’ble National Law Company Tribunal, Mumbai Bench (the “NCLT”), *inter alia*, directing the convening of the meetings of the shareholders of both the Transferor Company and the Transferee Company, for approving the Scheme of Amalgamation;
- (c) our letter dated October 26, 2024, enclosing the notice convening the meeting of the equity shareholders of the Transferee Company;
- (d) our letter dated November 28, 2024, informing about the approval of the Scheme of Amalgamation by the shareholders of the Transferee Company with requisite majority; and
- (e) our letter dated March 27, 2025, informing about the order of the NCLT, pronounced on March 27, 2025 (as uploaded on the official website of the NCLT on March 27, 2025 (<https://nclt.gov.in/>)) (the “Order”), sanctioning the Scheme of Amalgamation.

In this connection, we would like to inform that the Transferee Company has received the requisite approval from the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India *vide* letter dated April 22, 2025 (the “**Approval Letter**”) under the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019, as amended from time to time, for the potential increase of the aggregate foreign investment in the Transferee Company above 74% subsequent to the Scheme of Amalgamation, as per the terms and conditions prescribed in the Approval Letter.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

The Effective Date (*as defined in the Scheme of Amalgamation*) of the merger will be the opening business hours of the first day of the month immediately succeeding the month in which the last of the conditions specified in the Scheme of Amalgamation are fulfilled. The Effective Date will be communicated to the stock exchanges for further public dissemination as and when such conditions are fulfilled.

We request you to take this disclosure on your records.

This is for your information and records.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236